Fujifilm to develop large-scale cell culture manufacturing site in U.S.
By Nikita Chaurasia  Date: 2021-01-08

Fujifilm to develop large-scale cell culture manufacturing site in U.S.

In a bid to proliferate its biopharmaceutical contract development and manufacturing business, Fujifilm Corporation is reportedly planning to invest around USD 2 billion (200 billion yen) towards the development of a large-scale cell culture manufacturing site in the United States.

A subsidiary of this Tokyo-based multinational conglomerate, FUJIFILM Diosynth Biotechnologies, which also has production facilities in Denmark, the United Kingdom, as well as the United States will operate the new facility, cited sources with relevant information.

The new manufacturing facility will reportedly offer large-scale cell culture production capabilities of bulk drug substances with 8 x 20,000L bioreactors, with a potential to grow and add 24 x 20,000L bioreactors as per the market demand. The facility will also offer automated assembly as well as packaging and labeling services. Sources confirmed that this new site is likely to begin operations by the spring of 2025.

According to the President of Fujifilm Corp. Kenji Sukeno, the fresh investments will allow the company to develop as well as manufacture new drugs which can cater to the unmet medical demands. He added that the company intends to promote human health while supporting the growth of the healthcare sector by employing its advanced technologies and facilities to offer a continuous supply of state-of-the-art biopharmaceuticals.

Meanwhile, Martin Meeson, CEO at FUJIFILM Diosynth Biotechnologies mentioned that the Japanese conglomerate will deploy its expertise in biopharmaceutical development as well as manufacturing for producing vaccines, gene therapies, recombinant proteins, and antibodies.

Fujifilm is focusing on expanding its end-to-end service offerings throughout its biopharmaceutical CDMO businesses, sources claimed. The company reportedly invested around USD 928 million in its Denmark site FUJIFILM Diosynth Biotechnologies' Hillerød, to boost its cell culture production capacities as well as to add commercial-scale drug manufacturing capabilities.

It is worth mentioning that Fujifilm intends to achieve a yearly revenue of USD 2 billion for its biopharmaceutical CDMO (contract development and manufacturing) business by March 2025. Reportedly, the company believes that the fresh investment will boost its bio CDMO business annual growth rate to 20%, exceeding market predictions.

Source Credits –

https://www.prnewswire.com/news-releases/fujifilm-to-invest-over-200-billion-yen-2-billion-usd-to-establish-new-large-scale-cell-culture-manufacturing-site-for-biopharmaceuticals-in-the-usa-301202418.html

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

ClaimBuddy secures undisclosed sum in Titan Capital-led funding round
ClaimBuddy secures undisclosed sum in Titan Capital-led funding round
By Nikita Chaurasia

Indian insurance technology startup ClaimBuddy has reportedly raised an undisclosed amount in a seed funding round which was led by Titan Capital and involved participation from other marquee investor groups including First Cheque as well as LV Angel...

Mercedes-Benz unveils the EQA SUV in a bid to outdo Tesla, Volkswagen
Mercedes-Benz unveils the EQA SUV in a bid to outdo Tesla, Volkswagen
By Nikita Chaurasia

Daimler AG owned German automotive giant, Mercedes-Benz, has reportedly introduced the EQA, a new electric compact SUV to compete with market leader Tesla, Inc. as well as to meet its carbon targets in China and Europe. The Mercedes-Benz EQA, one of...

New York planning on direct purchase of Pfizer’s COVID-19 vaccines
New York planning on direct purchase of Pfizer’s COVID-19 vaccines
By Nikita Chaurasia

In recent developments, Governor of New York, Andrew Cuomo has reportedly issued a letter to the CEO of American drug maker Pfizer Inc., Albert Bourla, requesting for direct purchase of COVID-19 vaccine doses. Although the company is not bound to any...

Mayo Clinic Laboratories forms alliance with American Hospital Dubai
Mayo Clinic Laboratories forms alliance with American Hospital Dubai
By Nikita Chaurasia

In recent developments, Minnesota-based Mayo Clinic Laboratories and American Hospital Dubai are reportedly planning on entering a strategic alliance which is aimed at enhancing advanced laboratory diagnostic services in Dubai. Under the terms of th...

LTI, IBM extend global partnership to spearhead digital transformation
LTI, IBM extend global partnership to spearhead digital transformation
By Nikita Chaurasia

The New York-headquartered IBM Corp., with its global partner Larsen Toubro Infotech, an Indian global IT solutions & services company, are planning to extend their multi-year partnership, in a bid to enable companies to revolutionize the busines...